Drug Search Results
More Filters [+]

Poziotinib

Alternative Names: poziotinib, hm781-36b, nov120101, HM781-36
Latest Update: 2024-05-24
Latest Update Note: Clinical Trial Update

Product Description

Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. (Sourced from: https://www.sppirx.com/347-spectrum-products-development-poziotinib.html)

Mechanisms of Action: ERBB2 Inhibitor,TK Inhibitor,EGFR Inhibitor,ERBB4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Non-Small-Cell Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Poziotinib

Countries in Clinic: Japan, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PINNACLE

P3

Suspended

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2027-12-25

NCI-2017-00831

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2025-12-31

JapicCTI-205304

P2

Active

Non-Small-Cell Lung Cancer

2025-03-31

SPI-POZ-501

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2024-10-24

Recent News Events